Background
==========

Congenital heart disease is the most prevalent form of developmental abnormality in newborns, with an estimated prevalence of 1%, and is the leading non-infectious cause of infant mortality, with more than 29% of neonates who die of a birth defect having a cardiovascular deformity \[[@b1-medscimonit-18-6-cr344]\]. Congenital cardiovascular anomaly is clinically classified into at least 18 different types, with many additional anatomic variations, of which ventricular septal defect (VSD) is the most common type. VSD occurs in 30--60% of all children, with various kinds of congenital cardiovascular deformations, and accounts for 14--16% of birth defects that require an invasive procedure within the first year of life \[[@b1-medscimonit-18-6-cr344]--[@b3-medscimonit-18-6-cr344]\]. Congenital VSD can occur by itself or in combination with other cardiac malformations such as atrial septal defect, tetralogy of Fallot, and patent ductus arteriosis \[[@b1-medscimonit-18-6-cr344],[@b2-medscimonit-18-6-cr344],[@b4-medscimonit-18-6-cr344],[@b5-medscimonit-18-6-cr344]\]. Regardless of other potential conditions that accompany VSD, isolated moderate-to-large VSD with persistent left-to-right shunting of blood may give rise to cardiac enlargement, ventricular dysfunction, pulmonary hypertension, Eisenmenger's syndrome, delayed fetal brain development, arrhythmias, and even sudden cardiac death in the absence of surgical or catheter-based repair \[[@b6-medscimonit-18-6-cr344]--[@b13-medscimonit-18-6-cr344]\]. Despite the high incidence and the significant association of VSD with substantial morbidity and mortality in human, the etiology of VSD remains largely unclear \[[@b14-medscimonit-18-6-cr344],[@b15-medscimonit-18-6-cr344]\].

Abnormally developed interventricular septum is implicated in a heterogeneous, complex pathogenic process, for which both environmental risk factors and genetic defects may be responsible \[[@b2-medscimonit-18-6-cr344],[@b14-medscimonit-18-6-cr344]--[@b16-medscimonit-18-6-cr344]\]. Recently, growing evidence points to a crucial role of the zinc finger transcription factor GATA4 in the cardiogenesis \[[@b17-medscimonit-18-6-cr344],[@b18-medscimonit-18-6-cr344]\]. The human *GATA4* gene maps to chromosome 8p23.1-p22 and comprises 7 exons encoding a protein of 442 amino acids \[[@b19-medscimonit-18-6-cr344]\]. It is expressed throughout embryonic development and also in the adult heart \[[@b17-medscimonit-18-6-cr344],[@b18-medscimonit-18-6-cr344]\]. Therefore, *GATA4* has been one of prime candidate genes in identifying the molecular components underlying structural congenital heart defects. Presently, over 22 germline mutations in the coding exons of the *GATA4* gene have been identified in patients with a wide variety of congenital heart anomalies, including VSD, atrial septal defect, atrioventricular septal defect, tetralogy of Fallot, and endocardial cushion defect \[[@b20-medscimonit-18-6-cr344]--[@b33-medscimonit-18-6-cr344]\]. Nevertheless, VSD is genetically heterogeneous and the heritable determinants leading to VSD in the majority of cases are still to be identified.

Material and Methods
====================

Study participants
------------------

A cohort of 230 unrelated patients with VSD, including 205 cases with apparently sporadic VSD and 25 index patients with familial VSD, was identified among a Chinese Han population. Subjects were evaluated by individual and familial history, review of the medical records, complete physical examination, 12-lead electrocardiogram (ECG) and two-dimensional transthoracic echocardiography with color flow Doppler. All patients had a classic form of VSD, with a defect diameter of \>3 mm and nearly all patients underwent cardiac catheterization and, if required, cardiac surgery. The available family members of the probands harboring identified *GATA4* mutations were enrolled and evaluated by medical history, medical records, physical examination, ECG and echocardiography with color flow Doppler. A total of 200 ethnically matched unrelated healthy individuals, recruited from the general population, were used as controls to screen for likely mutations in *GATA4*. Peripheral venous blood specimens from VSD patients, available relatives of the mutation carriers, and control individuals were prepared. The study protocol was reviewed and approved by the local institutional ethics committee and written informed consent was obtained from all participants or their guardians prior to investigation.

Genetic studies
---------------

Genomic DNA from all participants was extracted from blood lymphocytes with Wizard Genomic DNA Purification Kit (Promega). The candidate gene *GATA4* was screened initially in 230 unrelated patients with VSD. Genotyping *GATA4* in the available relatives of an index patient carrying an identified mutation and the 200 ethnically matched unrelated healthy control individuals was conducted subsequently. The referential genomic DNA sequence of *GATA4* was derived from GenBank (accession No. NC_000008). By the aid of on-line Primer 3 software (*<http://frodo.wi.mit.edu>*), the primer pairs used to amplify the coding exons and exon/intron boundaries of *GATA4* by polymerase chain reaction (PCR) were designed, as shown in [Table 1](#t1-medscimonit-18-6-cr344){ref-type="table"}. The PCR was carried out using HotStar Taq DNA Polymerase (Qiagen) on a PE 9700 Thermal Cycler (Applied Biosystems), with standard conditions and concentrations of reagents. Amplified products were analyzed on 1% agarose gels stained with ethidium bromide and purified with QIAquick Gel Extraction Kit (Qiagen). Both strands of each PCR product were sequenced with a BigDye^®^ Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) under an ABI PRISM 3130 XL DNA Analyzer (Applied Biosystems). The sequencing primers were the same as previously designed for amplification of specific regions. The DNA sequences were viewed and analyzed with the DNA Sequencing Analysis Software v5.1 (Applied Biosystems). The variant was validated by re-sequencing an independent PCR-generated amplicon from the subject and met our quality control thresholds with a call rate \>99%.

Multiple sequence alignments
----------------------------

The multiple GATA4 protein sequences across species were aligned using the online program of CLUSTALW (*<http://www.bioinformatics.nl/tools/clustalw.html/>*).

Results
=======

Characteristics of the study subjects
-------------------------------------

A cohort of 230 unrelated patients with VSD was enrolled and clinically evaluated in contrast to a cohort of 200 ethnically matched unrelated healthy individuals as controls. None of them had apparent traditional risk factors for VSD. The baseline clinical characteristics of the 230 unrelated patients with VSD are summarized in [Table 2](#t2-medscimonit-18-6-cr344){ref-type="table"}.

*GATA4* mutations
-----------------

Direct sequencing of the coding exons of the *GATA4* gene was conducted after PCR amplification of genomic DNA from the 230 unrelated VSD patients. Four heterozygous missense mutations in *GATA4* were identified in 4 out of 230 patients. The total population prevalence of *GATA4* mutations based on the cohort patients was approximately 1.74%. Specifically, displacement of adenine by guanine in the second nucleotide of codon 55 of the *GATA4* gene (c.164A\>G), equivalent to the replacement of glutamine by arginine at amino acid 55 (p.Q55R), was identified in the proband from family 1. Substitution of adenine for guanine in the first nucleotide of codon 96 of the *GATA4* gene (c.286G\>A), predicting the transition of glycine to arginine at amino acid position 96 (p.G96R), was identified in the index patient from family 2. A change of adenine into guanine in the second nucleotide of codon 197 of the *GATA4* gene (c.590A\>G), corresponding to the transversion of asparagine to serine at amino acid residue 190 (p.N197S), was identified in the proband from family 3. A *GATA4* sequence variation of c.1211A\>G, resulting in the conversion of lysine into arginine at amino acid 404 (p.K404R), was identified in the proband from family 4. The sequence chromatograms showing the detected heterozygous *GATA4* mutations in comparison with control sequences are shown in [Figure 1](#f1-medscimonit-18-6-cr344){ref-type="fig"}. The variants were not detected in 200 control individuals and they are not described in the human SNP database (*<http://www.ncbi.nlm.nih.gov/SNP/>*). Genetic scan of the available family members of the mutation carriers demonstrated that in each family the variant was present in all affected family members, but absent in unaffected family members who were tested. Analysis of the pedigrees showed that each mutation co-segregated with VSD in the family with complete penetrance. The pedigree structures of the families are illustrated in [Figure 2](#f2-medscimonit-18-6-cr344){ref-type="fig"}. The phenotypic characteristics and results of genetic screening of the affected pedigree members are listed in [Table 3](#t3-medscimonit-18-6-cr344){ref-type="table"}.

Multiple alignments of the *GATA4* protein sequences across species
-------------------------------------------------------------------

A cross-species alignment of multiple GATA4 protein sequences showed that the affected amino acids of Q55, G96, N197, and K404 were completely conserved among mammals, as shown in [Figure 3](#f3-medscimonit-18-6-cr344){ref-type="fig"}, suggesting that these amino acids are functionally important.

Discussion
==========

In the present study, 4 novel heterozygous missense mutations of *GATA4* were identified in 4 families with congenital VSD. In each family, the mutation was present in all the affected family members alive but absent in unaffected relatives tested and 400 normal chromosomes from a matched control population. A cross-species alignment of GATA4 protein sequences demonstrates that the altered amino acids were highly conserved evolutionarily. Therefore, it is very likely that mutated GATA4 is involved in the pathogenesis of VSD in these families.

GATA transcription factors are a family of transcription factors characterized by the ability to bind to the consensus DNA sequence 'GATA'. To date, 6 members of the GATA family have been identified in vertebrates, of which GATA4, GATA5 and GATA6 are expressed mainly in the developing heart and in several endodermal lineages \[[@b34-medscimonit-18-6-cr344]\]. Structurally, GATA4 comprises 2 transcriptional activation domains (TAD1, amino acids 1--74; TAD2, amino acids 130--177), 2 zinc finger domains (ZF1, amino acids 215--240; ZF2, amino acids 270--294), 1 nuclear localization signal (NLS, amino acids 295--324), and 1 C-terminus (C-ter, amino acids 325--442) \[[@b35-medscimonit-18-6-cr344]\]. The 2 TADs are essential for the transcriptional activity of GATA4. The C-terminal ZF1 is required for DNA sequence recognition and binding to the consensus motif, while the N-terminal ZF2 is responsible for sequence specificity and stability of protein-DNA binding. The NLS sequence is associated with the subcellular trafficking and distribution of GATA4. The C-terminus is a regulator of the transcriptional activity of GATA4 \[[@b35-medscimonit-18-6-cr344]\]. The GATA4 mutation p.Q55R identified in this study is located in TAD1, and thus may be expected to exert direct influence on the transactivating activity of GATA4. The other 3 GATA4 mutations, including p.G96R and p.N197S located in the neighbor of TADs and p.K404R located in the C-terminus, may indirectly influence the transcriptional activity of GATA4 by altering the molecular conformation.

Our results are supported by the reports of other *GATA4* mutations associated with congenital cardiac septal defects. Presently, at least 13 out of 22 germline mutations identified in the coding region of the *GATA4* gene (p.H28Y, p.A66T, p.P163S, p.E216D, p.G296S, p.G296R, p.Q316E, p.S377G, p.V380M, p.P407Q, p.A411V, p.D425N, and p.H436Y) have been associated with isolated or syndromic VSD, showing that although *GATA4* mutations underlie a long list of cardiac developmental aberrations, one of the most common phenotypes ascribed to mutations of the *GATA4* gene is VSD \[[@b20-medscimonit-18-6-cr344]--[@b33-medscimonit-18-6-cr344]\]. However, the prevalence of GATA4 mutations varies significantly in different cohorts of individuals with congenital heart diseases. According to the 12 reports on the prevalence of GATA4 mutations in different cohorts of patients with VSD, the detection frequencies of GATA4 mutations are 12.50% (2/16) \[[@b23-medscimonit-18-6-cr344]\], 10.00% (5/50) \[[@b29-medscimonit-18-6-cr344]\], 6.90% (2/29) \[[@b22-medscimonit-18-6-cr344]\], 3.74% (4/107) \[[@b26-medscimonit-18-6-cr344]\], 3.23% (1/31) \[[@b30-medscimonit-18-6-cr344]\], 2.47% (12/486) \[[@b28-medscimonit-18-6-cr344]\], 1.67% (2/120) \[[@b24-medscimonit-18-6-cr344]\], 1.48% (2/135) \[[@b31-medscimonit-18-6-cr344]\], 0.80% (5/628) \[[@b25-medscimonit-18-6-cr344]\], 0.49% (1/205) \[[@b27-medscimonit-18-6-cr344]\], 0.48% (1/210) \[[@b33-medscimonit-18-6-cr344]\], and 0% (0/99) \[[@b36-medscimonit-18-6-cr344]\], and the prevalence in the compound population is 1.75% (37/2116). Similar to these findings, the mutational prevalence in our VSD cohort was 1.74% (4/230), suggesting that *GATA4* mutations are an uncommon cause of congenital cardiovascular defects. Additionally, based on known mutation sites, no mutation hot spots exist within the *GATA4* gene and the penetrance of different *GATA4* mutations differs considerably, which may be ascribed to genetic backgrounds, environmental modifiers, epigenetic regulations, or even phenotypic ascertainment bias. Furthermore, the remarkable genetic heterogeneity of VSD was supported by a failure to detect mutations in nearly 98% of our cohort patients. Hence, the contribution of genes other than *GATA4* to VSD pathogenesis appears likely.

Mutations in other transcription factors associated with cardiogenesis, such as NKX2-5 \[[@b37-medscimonit-18-6-cr344],[@b38-medscimonit-18-6-cr344]\], TBX5 \[[@b39-medscimonit-18-6-cr344],[@b40-medscimonit-18-6-cr344]\], TBX20 \[[@b41-medscimonit-18-6-cr344],[@b42-medscimonit-18-6-cr344]\], and GATA6 \[[@b43-medscimonit-18-6-cr344],[@b44-medscimonit-18-6-cr344]\], have also been identified in patients with VSD. In addition, mutations in cardiac structural proteins as troponin I type 3 (TNNI3) and alpha myosin heavy chain (MYH6) were identified in VSD patients \[[@b45-medscimonit-18-6-cr344],[@b46-medscimonit-18-6-cr344]\]. Therefore, genetic analysis of these candidate genes in our cohort patients with VSD is warranted. However, these VSD-associated genes have also been reported to result in other cardiac or even extracardiac defects that underlie the clinical heterogeneity and the suggestive roles of the established genotype-phenotype relations of these genes. Interestingly, *NKX2-5* mutations were mainly reported to cause atrial septal defect and atrioventricular block, implying the essential role of *NKX2-5* in the morphogenesis of the heart and in the construction of the cardiac conduction system \[[@b47-medscimonit-18-6-cr344]--[@b49-medscimonit-18-6-cr344]\]. Moreover, *TBX5* mutations were predominantly found to cause Holt-Oram Syndrome, which is clinically characterized by upper limb and heart defects. Despite the variable clinical manifestations, upper limb abnormalities were always present, highlighting the pivotal role of *TBX5* in the development of both heart and upper limbs \[[@b50-medscimonit-18-6-cr344]\]. In the present study, no patients had extracardiac defects. A compound phenotype of VSD and atrioventricular block was observed in 3 out of 230 patients. Genetic screening of *NKX2-5* in the 3 patients was performed, but no non-synonymous variants were found, largely excluding the possibility of *NKX2-5* as a cause for VSD combined with atrioventricular block in these patients.

Association of compromised *GATA4* with increased susceptibility to VSD has been demonstrated in animal experiments. In the embryonic hearts of knock-down chicks generated by using small interfering RNAs targeted to GATA4, the bilateral myocardial rudiments failed to travel to the midline, resulting in the formation of 2 separate hearts in lateral positions, an anomaly of cardia bifida \[[@b51-medscimonit-18-6-cr344]\]. In mice, GATA4 is one of the earliest transcription factors expressed in developing cardiac cells and continues to be expressed abundantly in cardiomyocytes throughout the life of mice \[[@b52-medscimonit-18-6-cr344]\]. Homozygous *GATA4*-deficient mice died between day 7.0 to 9.5 and analysis of the *GATA4*-null embryo substantiated the lethal failure to form a linear heart tube \[[@b53-medscimonit-18-6-cr344],[@b54-medscimonit-18-6-cr344]\]. Transgenic mice expressing *GATA4* mutants demonstrated a wide variety of cardiac malformations, including septal defects, right ventricular hypoplasia, endocardial cushion defect, tetralogy of Fallot, double outlets of the right ventricle, and cardiomyopathy, similar to the anomalies seen in humans \[[@b53-medscimonit-18-6-cr344],[@b54-medscimonit-18-6-cr344]\]. Taken together, these experimental results from animals suggest that *GATA4* mutations underlie a wide variety of congenital cardiac abnormalities, including VSD in humans.

Conclusions
===========

The findings link novel GATA4 mutations to VSD and provide additional insight into the molecular etiology associated with VSD, suggesting potential implications for the prophylaxis and therapy of VSD.
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###### 

The intronic primers to amplify the coding exons and exon-intron boundaries of *GATA4.*

  Exon   Forward primer (5′ to 3′)          Reverse primer (5′ to 3′)          Amplicon (bp)
  ------ ---------------------------------- ---------------------------------- ---------------
  2-a    GAT, CTT, CGC, GAC, AGT, TCC, TC   GTC, CCC, GGG, AAG, GAG, AAG       458
  2-b    GCT, GGG, CCT, GTC, CTA, CCT       AAA, AAC, AAG, AGG, CCC, TCG, AC   554
  3      GGG, CTG, AAG, TCA, GAG, TGA, GG   GAT, GCA, CAC, CCT, CAA, GTT, CC   437
  4      GAG, ATC, TCA, TGC, AGG, GTC, GT   GCC, CCT, TCC, AAA, TCT, AAG, TC   390
  5      TCT, TTC, TCG, CTG, AGT, TCC, AG   GGG, ATG, TCC, GAT, GCT, GTC       379
  6      GCC, ATC, CCT, GTG, AGA, ACT, GT   GAG, GGT, AGC, TCA, CTG, CTT, GC   444
  7      AAG, TGC, TCC, TTG, GTC, CCT, TC   TTC, CCC, TAA, CCA, GAT, TGT, CG   479

###### 

Clinical characteristics of the 230 unrelated patients with ventricular septal defects.

                                            Number or mean value   Percentage or range
  ----------------------------------------- ---------------------- ---------------------
  Male: female                              122: 108               53: 47
  Age at the diagnosis of VSD (year)        3.4                    1--16
  Age at the present study (year)           5.2                    1--20
  Positive family history                   25                     11
  Distribution of different types of VSDs                          
   Subarterial                              9                      4
   Perimembranous                           183                    80
   Atrioventricular canal                   10                     4
   Muscular                                 28                     12
  Prevalence of VSDs with other defects                            
   Isolated VSD                             215                    93
   VSD and ASD                              9                      4
   VSD and ASD and PDA                      2                      1
   VSD and ASD and DORV                     2                      1
   VSD and PDA                              4                      2
   VSD and PS                               2                      1
  Incidence of arrhythmias                                         
   Atrioventricular block                   3                      1
   Atrial fibrillation                      2                      1
  Treatment                                                        
   Surgical repair                          141                    61
   Transcatheter closure                    83                     36
   Follow-up                                6                      3

VSD -- ventricular septal defect; ASD -- atrial septal defect; PDA -- patent ductus arteriosus; DORV -- double outlet right ventricle; PS -- pulmonary stenosis.

###### 

Phenotypic characteristics and status of the GATA4 mutations in the affected pedigree members.

  Subject Information   Phenotypes   Genotypes                        
  --------------------- ------------ ----------- ---- ---- ----- ---- -------
  Family 1                                                            Q55R
   I-2                  F            30          12   5          −    +/−
   II-1                 F            5           3    13         −    +/−
  Family 2                                                            G96R
   I-1                  M            36          18   6    ASD   \+   +/−
   II-1                 M            7           7    3          −    +/−
   II-3                 F            1           1    7    PDA   −    +/−
  Family 3                                                            N197S
   I-1                  M            32          7    11   PS    −    +/−
   II-1                 F            2           2    15         −    +/−
  Family 4                                                            K404R
   II-1                 M            2           2    8          −    +/−

M -- male; F -- female; VSD -- ventricular septal defect; ASD -- atrial septal defect; PDA -- patent ductus arteriosus; PS -- pulmonary stenosis; AVB -- atrioventricular block. + indicates present and -- denotes absent.
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